NSE: DIVISLAB | BSE: 532488

Expensive Star

Download real time

6938.00 49.50 (0.72%)

New 52W High today

565.6K NSE+BSE Volume

NSE 08 Jul, 2025 3:31 PM (IST)

184,182.1

Market Cap

Market Runner Up

0.7

Beta 1Year

Very Low volatility

Dividend

Divi's Laboratories Ltd. has an upcoming dividend of ₹30.00 per share due on 25 Jul 2025 See details

Divi's Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DIVISLAB, BSE:532488 Divi's Laboratories Ltd.

Divi's Laboratories Ltd.

18 Sep 2018

6938.00

0.72%

Divis Labs

Buy: Divi's Laboratories Ltd.

Target

Sharekhan

Rupee reset pushes up estimates: In the past five months, rupee has depreciated by 10-11%, benefitting exporting pharma companies in terms of better sales realisation and profitability. Hence, we have revised our INR assumptions to Rs. 69 vs. earlier Rs. 67 (for FY2020E and FY2021E), leading to upgrade of 2-3% each in our sales and earnings estimates (FY2020E and...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

06 Aug 2018

6938.00

0.72%

Divi's Labs (1QFY19): Low visibility on growth. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

Target

HDFC Securities

Maintain NEUTRAL rating, with a revised TP of Rs 1,150 (22x FY20E). 1QFY19 is a seasonally weak quarter for Divis Lab, but on a lower base of last year which was affected by import alert, the YoY expectations were higher. The top-line came in at Rs 10bn (in-line), up ~21%YoY (down 9% QoQ). Strong growth in the generics (+26% YoY) and nutraceuticals businesses (+61%YoY) boosted the top-line.

Divi's Laboratories Ltd. has gained 31.93% in the last 3 Months

Divi's Laboratories Ltd.

06 Aug 2018

6938.00

0.72%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 21.2% YoY to | 995.3 crore (I-direct estimate: | 1151.2 crore) mainly due to lower base of import alert in Q1FY18, currency tailwinds and strong growth in the carotenoid segment EBITDA margins improved 554 bps to 35.4% (I-direct estimate: 36%) mainly due to strong gross margins, lower other expenditure. EBITDA grew 43.7% YoY to | 351.9 crore (I-direct estimate: | 414.4 crore) Net profit grew 50.8% to | 266.2 crore (I-direct estimate: | 308.1...

Divi's Laboratories Ltd. has gained 49.86% in the last 1 Year

Divi's Laboratories Ltd.

04 Aug 2018

6938.00

0.72%

Strong growth partly on low base; On track to improve profitability

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

4 August 2018 revenue grew 21% YoY to INR10b (our estimate of INR10.5b). The strong YoY growth came partly on the back of last years low base. The business slowdown at Unit-I due to compliance-related activities during the quarter impacted the growth to some extent. Gross margin expanded by ~200bp YoY to 62%, but contracted by ~100bp QoQ due to change in product mix, higher prices of solvents on account of hike in crude oil prices and increase in prices of key starting material procured from China. EBITDA margin improved more sharply than gross margin by 554bp YoY to 35.4% for the quarter, driven largely by a reduction in costs related to remediation measures. Other expenses, as a percentage of sales, declined from 18.2% in 1QFY18 to 14.1% in 1QFY19. EBITDA grew 43.7% YoY to INR3.5b (our estimate of INR3.7b). PAT growth at 39% YoY was higher than EBITDA growth, led by forex gain of INR270m.

Divi's Laboratories Ltd. has gained 31.93% in the last 3 Months

Divi's Laboratories Ltd.

30 May 2018

6938.00

0.72%

Divi's Lab: Revenues in line, margins outperform

Hold: Divi's Laboratories Ltd.

Recommendation Target

Karvy

Revenues in line, margins outperform: Divis Lab's net revenues increased by 1.9% YoY to Rs 10.8 bn, marginallylower than our estimates of Rs 10.9 bn for the quarter. The operating marginswere at 35.5% in Q4FY18 (higher than our estimate of 33.9%) as against 34%in Q4FY17 on account of lower raw material cost and other expenses.

Divi's Laboratories Ltd. has gained 31.93% in the last 3 Months

Divi's Laboratories Ltd.

29 May 2018

6938.00

0.72%

Divi's Laboratories

Hold: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

EBITDA margins improved 159 bps to 35.5% (I-direct estimate of 33.7%) mainly due to strong gross margins and lower other expenditure. Gross margins improved 200 bps to 62.5% (I-direct...

Divi's Laboratories Ltd. has gained 49.86% in the last 1 Year

Divi's Laboratories Ltd.

28 May 2018

6938.00

0.72%

Divi's Labs (4QFY18): Low visibility on growth. Maintain NEUTRAL

Neutral: Divi's Laboratories Ltd.

Target

HDFC Securities

Maintain NEUTRAL rating, with a revised TP of Rs 1,095 (22x FY20E). After resolving the import alert for Unit 2, this was the 2nd consecutive quarter where Divis Lab (DIVIS) has maintained strong sequential improvement in its operational performance. Top line increased 5%QoQ/2%YoY, EBITDA at Rs 3.8bn was up 13%QoQ/-1.2%YoY and Reported PAT came in at Rs 2.6bn up 16%QoQ/0.9%YoY. EBITDA margin at 35.5% is suggesting that the business has returned to near normalcy. It was up 256bps QoQ/down 113bps YoY in 4QFY18.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

28 May 2018

6938.00

0.72%

Overall revenue came marginally ahead of estimate by ~5% at Rs10.8bn as against estimate...

Hold: Divi's Laboratories Ltd.

Target

Emkay

Overall revenue came marginally ahead of estimate by ~5% at Rs10.8bn as against estimate of Rs10.4bn. Overall net income stood at Rs2.6bn as against estimate of Rs2.42bn, helped by significantly higher other income. The highlight of Q4FY18 was a 200/400bps qoq expansion in gross margin/EBITDA margin. The additional EBITDA margin expansion is a result of remediation costs fading away, which should completely normalize in the next 1-2 quarters. short-term growth outlook for DIVI's is uncertain given the possible paucity of capacity. Valuation also looks challenging for DIVI's given the stock's run-up in the past few months,...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.

Divi's Laboratories Ltd.

26 May 2018

6938.00

0.72%

Margin surprises positively; charts expansion plan for coming years

Neutral: Divi's Laboratories Ltd.

Target

Motilal Oswal

Gross margin improved ~210bp YoY (~130bp QoQ) to 62.5%. This, along with a decline in other expenditure by ~180bp (as % of sales), led to margin expansion by ~180bp YoY to 35.5%. EBITDA rose ~8% YoY (+19% QoQ) to INR3.9b (est. PAT, however, grew by just 26 May 2018 ~1% YoY to INR2.6b, mainly due to a higher tax of 34% v/s 26% in 4QFY17. For FY18, sales, EBITDA and PAT stood at INR39b (-4.

Divi's Laboratories Ltd. is trading above all available SMAs

Divi's Laboratories Ltd.

02 Feb 2018

6938.00

0.72%

Result Update:Divis Lab.

Buy: Divi's Laboratories Ltd.

Target

Axis Direct

Q3FY18 revenue grew 6% YoY/ 17% QoQ (19%/ 11% YoY decline in Q1/ Q2), 9% ahead of our estimates, on resumption of supplies of non-exempted products and completion of USFDA resolution in Sept-Nov'17.

Divi's Laboratories Ltd. has gained 49.86% in the last 1 Year

Is Divi's Laboratories Ltd. worth buying?

750 Votes:

Buy 78.0%

Sell 15.07%

Hold 6.93%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf